Latest Treatment Strategies for Correcting Posterior Ocular Diseases with CRISPR-Cas9
Background and Challenges: A New Horizon in Retinal Disease Treatment
The retinal pigment epithelium (RPE) and photoreceptor cells, which are responsible for the posterior part of the retina, are gradually losing function due to genetic defects, especially in Leber congenital amaurosis type 10 (LCA10), caused by deep intronic mutations in the CEP290 gene. Currently, there is no cure, causing significant suffering for patients and their families. Traditional gene augmentation therapy is limited by the size of genes that can be packaged into AAV vectors, making it difficult to directly deliver large genes such as CEP290 (over 5kb), which hinders sustained protein expression in the eye. Furthermore, there are concerns that immune responses and off-target mutations may threaten long-term safety. These technical and biological barriers have highlighted the urgent need for a new therapeutic paradigm in ophthalmology. In this context, the CRISPR-Cas9 system, which can precisely cleave double-stranded DNA and insert desired sequences using the cell's own homology-directed repair (HDR) mechanism, has emerged as a promising approach. Researchers are exploring composite designs that simultaneously regulate tissue-specific promoters and limited immune responses, considering the microenvironment of the eye, with the ultimate goal of achieving lifelong vision restoration with a single administration.
Research Methods and Findings: CRISPR-Cas9 Accurately Corrects Target Genes
The research team used AAV2/8 viruses to deliver Cas9 and guide RNA to photoreceptor precursor cells. Cas9 was designed to induce double-strand breaks at specific promoter sites, activating the HDR pathway to restore the normal CEP290 sequence. In preclinical mouse models, this strategy restored the signaling of voltage-gated calcium channels (CaV1.4) located on the outer membrane of photoreceptors, and electrophysiological measurements showed that A-wave potentials returned to normal levels, with a 45% improvement observed in visual behavior tests. In clinical trials, programs such as EDIT-101 (beta version) showed an average increase of 0.1 logMAR units in best-corrected visual acuity (BCVA) in the central visual field in one-third of patients after 6 months, and off-target mutations were not detected by whole-genome sequencing, raising expectations for safety. In addition, a highly specific variant (Cas9-HF1) of Cas9, in which the RuvC domain was modified, was used to increase editing efficiency, which reduced the DNA damage response (ฮณ-H2AX) marker in RPE cells by 70%, minimizing cytotoxicity. These results suggest that the same editing efficiency can be expected in human retinas, and that when applied to actual patients, the effects of neuronal circuit reconstruction extending to the visual cortex should also be considered.
Future Implications or Prospects: Path to Clinical Application and Improved Safety
EDIT-103 and HG202, which are currently in Phase 2 clinical trials, target various genotypes of RPE mutations, and if successful, they could provide personalized gene therapy for approximately 20 million people worldwide each year who suffer from visual impairment. At the same time, researchers are developing non-viral lipid nanoparticle (LNP) delivery systems, which could enable systemic administration through the bloodstream, allowing editing tools to reach deep layers of the retina without surgery. Regulatory agencies require long-term follow-up data for off-target validation and certification of Cas9 variants that minimize immunogenicity, so ensuring data transparency will be the key to future commercialization. If these technical and regulatory hurdles can be overcome, ophthalmology will be able to apply CRISPR-based therapies to complex diseases such as genetic age-related macular degeneration (AMD), which has the potential to expand the entire ophthalmology market to 12 trillion won by 2028. Ultimately, when CRISPR-based therapies become part of standard treatment protocols, ophthalmologists will be able to select personalized editing strategies through genotyping and design long-term vision maintenance programs.
CRISPR-Cas gene editing has become increasingly relevant in the treatment of several ophthalmic diseases. Its ability to make precise modifications at the DNA or RNA level has enabled targeted approaches for specific mutations involved in conditions such as Leber congenital amaurosis type 10 (LCA10), certain forms of retinitis pigmentosa, and age-related macular degeneration. This article provides an organized overview of the biological basis of CRISPR-Cas technology and highlights key advances from preclinical studies and early clinical trials. Technical limitations and ongoing safety challenges are also discussed. Programs such as EDIT-101, EDIT-103, and HG202 stand out as important milestones in the evolution of ocular gene editing.
This research addresses the serious problem that inherited retinal degenerative diseases cause vision loss in more than 100 million people worldwide, and currently, only symptomatic relief is available. Existing gene augmentation therapies have been limited by AAV vector capacity and the risk of immune responses, making it difficult to deliver large genes or ensure long-term expression, leaving many patients without effective treatment options. By attempting direct DNA correction using CRISPR-Cas9 and highly specific variants, the research team presents a new approach that minimizes off-target risks and enables accurate HDR-based repair. This has shown promising results in ongoing Phase 2 clinical trials, with the potential to form a 2 trillion won ophthalmic gene therapy market annually, bringing tangible changes to both biotech companies and healthcare systems. In the future, large-scale Phase 3 trials and application studies for various ocular diseases will be conducted, and with the establishment of a regulatory framework, personalized gene editing therapies will become a routine clinical option.